-
-
-
-
-
-
-
Cytokinetics aficamten shows cardiac benefits in two HCM trial analyses
-
-
-
-
-
-
-
Cytokinetics wins UK approval for heart drug aficamten
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $105 at Jefferies
-
-
-
-
-
-
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $69 at UBS Amid Improved nHCM Outlook
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Cytokinetics (CYTK)
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $136 at H.C. Wainwright
-
479,068 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


